Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients.

Détails

ID Serval
serval:BIB_F288B9AFF79F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients.
Périodique
European Journal of Clinical Pharmacology
Auteur(s)
Soldini D., Zwahlen H., Gabutti L., Marzo A., Marone C.
ISSN
0031-6970 (Print)
ISSN-L
0031-6970
Statut éditorial
Publié
Date de publication
2005
Volume
60
Numéro
12
Pages
859-864
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
OBJECTIVE: N-acetylcysteine (NAC) is a mucolytic agent with anti-oxidant properties. It might have potential positive effects in renal patients and, therefore, its pharmacokinetics and safety in haemodialysis was investigated.
METHODS: Twelve dialysis patients received 2 g NAC (10 ml NAC 20% solution i.v.) mixed with 500 ml saline during the first 3 h of the session for six dialysis sessions. A bolus of heparin was injected intravenously as LWH-heparin. In six patients, one session was repeated with NAC mixed with heparin and infused through the heparin pump.
RESULTS: Baseline NAC was on average 454 ng ml(-1); its concentration increased to 9,253 ng ml(-1) at the second infusion and attained a steady state between 14,000 ng ml(-1) and 17,000 ng ml(-1) at the fourth dose. We observed a C (max) of 53,458 ng ml(-1) with a t (max) of 3.0 h. Plasma clearance was 1.25 l h(-1) and dialytic clearance 5.52 l h(-1). No side effects were observed.
CONCLUSION: In the case of repeated doses, the NAC pre-dose concentration after repeated infusion of 2 g of the drug during the first 3 h of a dialysis session reached the steady state at the fourth infusion, without further accumulation. The dialytic clearance is effective, the total body clearance being reduced to 1.25 l h(-1). In dialysis patients, 2 g NAC given intravenously over 3 h is a safe dosage, with no short-term side effects.
Mots-clé
Acetylcysteine/administration & dosage, Acetylcysteine/pharmacokinetics, Aged, Antioxidants/administration & dosage, Antioxidants/pharmacokinetics, Area Under Curve, Blood Urea Nitrogen, Cysteine/blood, Drug Administration Schedule, Expectorants/administration & dosage, Expectorants/pharmacokinetics, Female, Glutathione/blood, Humans, Infusions, Intravenous, Kidney Failure, Chronic/metabolism, Kidney Failure, Chronic/therapy, Male, Metabolic Clearance Rate, Middle Aged, Pilot Projects, Renal Dialysis
Pubmed
Création de la notice
24/07/2013 10:21
Dernière modification de la notice
16/04/2020 6:26
Données d'usage